2-Ethylpyrimidine-5-carbonitrile | 1060817-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Ethylpyrimidine-5-carbonitrile
• CAS: 1060817-38-0
• 化学式: C₇H₇N₃
• mdl: MFCD11053958
• 分子量: 133.15
• InChiKey: MIFBIJDNSKXRMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• WGK Germany：
  3

文献信息

• Azaindazole Compounds As CCR1 Receptor Antagonists
  申请人：COOK Brian Nicholas

  公开号：US20120035370A1

  公开（公告）日：2012-02-09

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.

  本发明涉及一种式（I）的化合物，用于治疗多种通过CCR1活性介导或维持的疾病和障碍，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。本发明还涉及其中间体以及制备和使用该化合物的方法。
• Pyridinyl Compounds Useful As Intermediates
  申请人：COOK Brian Nicholas

  公开号：US20120136158A1

  公开（公告）日：2012-05-31

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.

  本发明涉及一种式(I)的化合物，可用于治疗多种通过CCR1活性介导或维持的疾病和障碍，包括自身免疫性疾病，例如类风湿性关节炎和多发性硬化症。本发明还涉及其中间体，以及制备和使用它们的方法。
• PESTICIDALLY ACTIVE POLYCYCLIC DERIVATIVES WITH SULFUR SUBSTITUTED FIVE MEMBERED RING HETEROCYLES
  申请人：Syngenta Participations AG

  公开号：EP3286186B1

  公开（公告）日：2020-05-06
• SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME
  申请人：Nodthera Limited

  公开号：US20210087147A1

  公开（公告）日：2021-03-25

  The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.
• US8063065B2
  申请人：——

  公开号：US8063065B2

  公开（公告）日：2011-11-22